Mutant can analyze compatible genetic data from:
All supported DNA sources use the same Mutant analysis framework.
What changes is genetic coverage.
23andMe and AncestryDNA use genotyping technology that measures selected genetic locations.
Whole-genome sequencing reads much more broadly across the genome and therefore usually makes more of the genetic markers used by Mutant available.
The practical difference is:
Consumer DNA data can provide useful coverage with more gaps. Whole-genome sequencing generally provides broader coverage with fewer gaps.
You do not receive a different Mutant product because you use WGS.
Your complete raw DNA stays in your browser.
| 23andMe / AncestryDNA | Whole-Genome Sequencing | |
|---|---|---|
| Technology | Consumer genotyping / microarray | Whole-genome sequencing |
| Genetic locations available | Selected subset | Much broader |
| Mutant analysis framework | Same | Same |
| Mutant systems & hypotheses | Same framework | Same framework |
| Missing markers | More common | Less common |
| Relevant variant coverage | Usually lower | Usually higher |
| Best reason to use it | You already have the data and want to begin | You want broader genetic coverage |
| Need a different Mutant plan? | No | No |
| Can you use another DNA source later? | Yes | Yes |
The most important distinction is coverage, not access to different biological systems.
Services such as 23andMe and AncestryDNA generally use microarray genotyping.
A microarray does not read every position in your genome.
Instead, it tests a selected collection of genetic locations chosen by the provider.
Your resulting data may contain hundreds of thousands of genotype observations.
That is substantial genetic information.
But it is still only a subset of the genome.
Imagine that the human genome is a very large book.
A consumer genotyping array checks a large set of preselected words and sentences throughout the book.
Whole-genome sequencing attempts to read nearly the entire book.
Both can contain information Mutant uses.
The second simply provides many more opportunities for relevant markers to be available.
Whole-genome sequencing reads DNA across nearly the entire genome rather than testing only a predefined panel of locations.
Depending on the sequencing provider, processing pipeline, and resulting file, WGS may provide genetic information across:
For Mutant, the main advantage is straightforward:
More of the genetic markers used by Mutant's models may be available.
This can reduce the number of gaps in an analysis.
This distinction is important.
Whole-genome sequencing may contain millions of genetic variants.
Mutant does not attempt to interpret every one of them.
Mutant uses a defined set of genetic markers relevant to the biological systems and health hypotheses it currently models.
So when Mutant says WGS provides broader coverage, it means:
WGS generally provides broader coverage of the genetic evidence Mutant currently uses.
It does not mean:
Mutant's scope is determined by its models, not merely by how much data is present in the source file.
Consumer DNA data should not be treated as a placeholder.
If you already have compatible 23andMe or AncestryDNA data, it may provide enough coverage for Mutant to identify meaningful patterns across many biological areas.
Depending on your file and testing version, Mutant may be able to evaluate genetic context involving areas such as:
The limitation is not that consumer data creates an inferior type of analysis.
The limitation is that some genetic markers may simply be unavailable.
This is one of the most important differences between consumer genotyping and broader sequencing.
Suppose a Mutant model uses ten relevant genetic markers.
If your 23andMe or AncestryDNA data contains seven of them, Mutant can evaluate those seven.
The other three are missing.
Mutant should not interpret them as:
They are simply unavailable.
That distinction becomes especially important when interpreting a hypothesis with limited coverage.
Mutant tracks which genetic markers required by its models were available in your DNA data.
You may see this described as:
Relevant variant coverage
This means:
The proportion of genetic markers used by Mutant's current analysis that were available in your DNA data.
It does not mean:
The percentage of your entire genome that Mutant analyzed.
For example, a relevant variant coverage value of 60% does not mean Mutant analyzed 60% of the human genome.
It means approximately 60% of the markers Mutant wanted for that analysis were available from the provided DNA source.
A consumer DNA file may cover one Mutant hypothesis very well and another much less completely.
That happens because consumer genotyping arrays were not designed specifically around Mutant's models.
For example:
Most of its important genetic markers may happen to be included on a consumer array.
The available genetic evidence could therefore be relatively complete.
Several important markers may not have been tested by that provider.
Mutant may still identify some supporting evidence, but interpretation should reflect the missing data.
This is why one overall statement such as:
“23andMe is good enough”
or:
“23andMe cannot be used for health analysis”
is too simplistic.
The useful question is:
How much coverage does this particular DNA source provide for the biological models being evaluated?
Whole-genome sequencing is not restricted to a provider's preselected microarray markers.
That makes it more likely that genetic locations used across Mutant's models will be available.
Potential advantages include:
This can improve the completeness of the genetic evidence available to Mutant.
It does not automatically make every hypothesis stronger.
If broader sequencing reveals that a suspected pattern is not present, better coverage may actually weaken a hypothesis.
That is a feature, not a problem.
More DNA data should not simply make Mutant produce more findings.
It should make the evidence more complete.
Suppose a consumer DNA source provides partial evidence for a health hypothesis.
Broader sequencing could reveal:
The goal of WGS is therefore not:
Get a more dramatic report.
It is:
Reduce uncertainty caused by missing genetic information.
That question needs to be separated into two issues.
Different technologies, laboratories, sequencing depths, calling pipelines, and quality-control processes can affect the accuracy of individual variant calls.
A high-quality WGS dataset can provide excellent variant information.
But WGS is not automatically error-free.
This is the clearer distinction.
Microarrays intentionally test a selected subset of variants.
WGS covers far more of the genome.
For Mutant, the practical advantage is primarily broader availability of modeled genetic markers.
For many users, yes—especially if it is the DNA data they already have.
You do not need to purchase WGS before discovering whether Mutant provides useful genetic context.
A reasonable sequence is:
WGS is not required simply because it provides more data.
Consumer DNA data is a good starting point when:
There is little reason to discard useful existing genetic data simply because broader sequencing exists.
Whole-genome sequencing may be more attractive when:
The decision does not need to be made before trying Mutant.
Your Mutant account is not permanently tied to your original DNA source.
If you begin with compatible 23andMe or AncestryDNA data and later obtain supported WGS data, you can use the newer DNA source and regenerate your analysis.
Mutant can then determine which additional markers have become available and update the resulting evidence.
The biological framework remains the same.
What changes is the available genetic coverage.
23andMe, AncestryDNA, and supported WGS data are not separate Mutant product tiers.
The Mutant Free / Mutant Full distinction is based on access to your ranked health hypotheses, not on which DNA technology produced your data.
Mutant Free includes:
Your top 3 hypotheses can come from any biological system or hub.
No credit card required.
Mutant Full unlocks:
Using WGS does not require a different Mutant subscription.
These are two separate concepts.
Determines what genetic evidence is available.
More missing markers are likely.
Broader genetic coverage is generally available.
Determines how much of the resulting analysis you can open.
Top 3 ranked health hypotheses are fully available.
All ranked health hypotheses are fully available.
So a user could have:
The genetic-analysis framework does not change.
Whether you use consumer DNA data or WGS, Mutant is designed to minimize how much genetic information leaves your device.
When you select supported DNA data:
Mutant does not upload or store your complete raw DNA.
This is especially important for WGS because whole-genome files can contain far more genetic information than Mutant actually needs.
Whole-genome data can be:
Mutant does not need to retain the entire genome in order to analyze its current models.
Instead, the browser can identify the subset of genetic markers Mutant needs before those markers are sent.
This means:
Broader source data does not require Mutant to store your broader genome.
Coverage matters particularly when evaluating higher-impact inherited-health hypotheses.
Mutant may explore genetic context involving areas such as:
Consumer microarrays may contain some relevant variants while missing others.
WGS can provide broader visibility.
But even WGS data used by Mutant should not be treated as equivalent to clinically validated diagnostic genetic testing.
A potentially significant inherited finding may require:
A missing finding in Mutant should not be interpreted as proof that a genetic condition is absent.
Whole-genome sequencing provides much broader data, but it does not eliminate every limitation.
Depending on the sequencing technology and pipeline, challenges can remain in areas involving:
Mutant also evaluates only the genetic evidence incorporated into its current models.
So:
Broader sequencing does not mean unlimited interpretation.
Consumer genotyping datasets contain substantial gaps relative to WGS.
A system could attempt to fill some of those gaps statistically through genotype imputation.
But an inferred genotype is not equivalent to directly observed source data.
For health-related modeling, it is important to distinguish between:
Mutant's coverage model should make uncertainty visible rather than silently turning missing information into certainty.
A simple way to think about the relationship is:
Same Mutant analysis
+ useful genetic evidence
+ more missing markers
Same Mutant analysis
+ broader genetic evidence
+ fewer missing markers
There is no special "WGS version" of the Mutant biological model.
Yes.
Compatible 23andMe data can provide useful coverage across many Mutant models.
Some markers may be missing depending on your testing version.
Yes.
Compatible AncestryDNA data may also provide useful genetic coverage.
As with 23andMe, some markers used by Mutant may be unavailable.
No.
If you already have compatible consumer DNA data, you can begin with it.
No.
Mutant uses the same systems, models, converging patterns, and ranked health-hypothesis framework.
WGS generally provides broader input coverage.
Not as an entitlement.
Your Free or Full plan determines which ranked hypotheses you can open.
However, broader genetic coverage can change the evidence available to Mutant and therefore may affect:
That is a data-coverage effect, not a paid feature.
It may.
WGS can make additional genetic evidence available.
That may:
The underlying Mutant framework remains the same.
No different Mutant plan is required because of your DNA source.
Mutant Free and Mutant Full are based on hypothesis access, not whether your DNA came from microarray genotyping or WGS.
No.
WGS is much broader than consumer microarrays, but technical gaps can still occur.
Mutant also evaluates a defined set of markers rather than every possible genetic variant.
No.
Mutant extracts and analyzes the genetic markers required by its current models.
It does not attempt to interpret every variant present in a whole-genome dataset.
It describes how many of the genetic markers used by Mutant's analysis were available in your DNA data.
It is not the percentage of your genome analyzed.
No.
A missing marker is treated as missing data.
It should not be interpreted as:
Not simply because it is whole-genome data.
Sequencing quality, variant calling, interpretation, and clinical validation all matter.
Mutant provides educational genetic context.
Potentially important medical findings may need confirmation through appropriate clinical testing.
No.
Mutant may identify genetic patterns that warrant further investigation.
It does not replace clinical genetic diagnosis.
Yes.
You can begin with compatible consumer DNA and use a supported WGS source later.
Mutant can then regenerate your analysis using the broader available marker set.
No.
Your complete DNA data is read locally in your browser.
Only the genetic markers needed by Mutant's models are sent and retained.
No.
The questionnaire is optional.
It can provide additional Health Context, but Mutant's genetic analysis can be generated without it.
The simplest answer is:
Use it.
There is no need to delay your Mutant analysis simply because broader sequencing exists.
See what coverage your current data provides.
Use the WGS data.
It will generally provide broader coverage of Mutant's modeled variants.
You do not need WGS to begin.
Start with compatible genetic data you already have, review your relevant variant coverage, and decide whether reducing those gaps is worth purchasing broader sequencing.
23andMe, AncestryDNA, and whole-genome sequencing are not different Mutant products.
They are different sources of genetic evidence.
Provides a selected subset of genetic markers.
Provides much broader genomic coverage.
Uses the available markers from either source to run the same biological-systems and health-hypothesis framework.
The better question is therefore not:
Should I use the basic Mutant analysis or the WGS Mutant analysis?
There is only one analysis framework.
The question is:
How much of the genetic evidence Mutant uses is available from my DNA source?
Start with what you already have.
If broader sequencing later makes sense, you can use it to reduce coverage gaps and regenerate your analysis.
Your top 3 ranked health hypotheses are included in full with Mutant Free.
No credit card required.
Your complete raw DNA stays in your browser.
Mutant provides educational and informational genetic analysis. Its findings are health hypotheses, not diagnoses, and are not a substitute for clinical genetic testing, medical evaluation, or treatment.